Analyst Targets And Triggered Technicals Pin (Nasdaq: VERU) To Our Radar (Low Float)

A conference invitation is usually filler. This one is a marker.

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored Analyst Targets And Triggered Technicals Pin (Nasdaq: VERU) To Our Radar (Low Float) *Get Our Updates Faster—Tap Here To Receive SMS Alerts* September 8th Greetings, Friend! A conference invitation is usually filler. This one is a marker. Veru Inc. (Nasdaq: VERU) said last week that Chairman, President and Chief Executive Officer Mitchell Steiner, M.D., will hold a fireside chat at the 2026 Cantor Global Healt-hcare Conference on September 9th, his first scheduled appearance since a summer in which the company closed a study, cleared a patent and lined up supply with the largest name in wei-ght management. Start with the patent, because it reframes everything else. In early August the U.S. Patent and Trademark Office issued a notice of allowance on method of use claims covering enobosarm given with wei-ght lo-ss medicines, running to at least October 3rd, 2044. The claims are not narrow. They cover concurrent dosing with semaglutide, addition to an existing regimen, and continuation after semaglutide is stopped. A pending application on an oral modified release formulation could carry protection into 2046. Stated protection runway for the enobosarm combination estate. Source: Veru Inc. news release of August 4th, 2026. Underneath the filing sits evidence already generated. The completed Phase 2b QUALITY study enrolled 168 patients aged 60 and older receiving semaglutide. Enobosarm at 3 mg produced a 100% relative reduction in lean mass loss versus placebo at a p value below 0.001, and the 6 mg arm showed 42% greater relative fat mass loss at 16 weeks. On the measure that translates to daily life, the 3 mg arm cut the share of subjects losing at least 10% of stair climb power by 59.8%. Measured results versus placebo in the Phase 2b QUALITY study. Source: Veru Inc. cardiometabolic program disclosures. The confirmatory work is underway and fully staffed. PLATEAU closed enrollment at 239 patients, ahead of its roughly 200 patient target. It is double blind and placebo controlled, running 68 weeks in patients aged 65 and older with a body mass index of 35 or greater who are starting semaglutide. Interim data at 32 weeks is guided to early 2027, topline to the fourth quarter. The company also strengthened its footing over the same period. Cash and restricted cash reached $23.9Mn at June 30th against $15.8Mn at the close of fiscal 2025, with total stockholders' equity of $28.4Mn, and Chief Financial Officer Michele Greco said on the call that the balance is expected to fund operations beyond the interim analysis. About Veru Inc. (Nasdaq: VERU) Veru Inc. is a late clinical stage biopharmaceutical company based in Miami, FL, focused on cardiometabolic and inflammatory disease. Enobosarm, the lead asset, is an oral selective androgen receptor modulator evaluated in six clinical trials across more than 1,100 patients, with consistent gains in lean mass and improved physical function. The second molecule, sabizabulin, targets chronic inflammation related to atherosclerotic cardiovascular disease and depends on additional funding. Value accrues through clinical milestones, patent claims and partnering. The Company reached this structure through divestiture rather than acquisition. Veru sold its FC2 consumer health business for $18Mn at the end of December 2024, netting roughly $12.5Mn, retiring a $9.9Mn royalty liability and reducing headcount from about 210 to 22. CEO Mitchell Steiner called it the step that let Veru operate as a pure biopharmaceutical company. Sector Analysis: Where This Theme Sits The category is large and still growing, but second order questions are where the next differentiation comes from. Morgan Stanley Research put its 2035 base case at $190Bn against $79Bn in 2025, with United States adoption rising toward roughly 30% of the obese and diabetic population. Goldman Sachs Research projected the category could approach $120Bn by 2035.  Veru cites obesity prevalence of 41.5% among the 47.4Mn people in Medicare Part D plans, and notes current therapies reach less than 2% of eligible patients. The Third Quarter Call Management's framing on the August call was structural rather than promotional. Chief Executive Officer Mitchell Steiner returned repeatedly to one figure, that 62.6% of patients still had clinical obesity when they reached the one year plateau, and argued older patients are most exposed to falling below a critical muscle threshold. He flagged that Medicare coverage of G-L-P-1 therapies began on July 1st, 2026, and confirmed that Novo Nordisk supplies Wegovy for the study at no charge in return for a right of first negotiation on combination rights. There Are 7 Key Potential Catalysts Putting (Nasdaq: VERU) On Our Radar #1. Allowed Claims Extend Almost Two Decades Past Today. The method of use claims run to at least October 3rd, 2044, turning the VERU asset from a study result into a defensible commercial position. #2. A Fully Enrolled Study With A Scheduled Interim Look. PLATEAU finished enrollment at 239 patients and the 32 week interim analysis for VERU is guided to early 2027. #3. A Float Under 16Mn Shares May Create Potential For Heightened Volatility. With approx. 15.48Mn shares in its float, VERU screens as a low float idea, meaning the potential for heightened volatility may be significant. #4. Technical Indicators Are Flashing Bullish Signals Across Terms. Barchart.com's Opinion page reported 12 of 13 technical indicators it tracks to be triggered at close on Friday. This includes the website’s composite “Trend Seeker” indicator. #5. Reimbursement Policy Moved Toward The Target Cohort. Medicare coverage of G-L-P-1 therapies began on July 1st, 2026, addressing the payer question that has long sat over the exact population VERU is studying. #6. VERU Has 2 Analyst Targets Pointing To Significant Upside Potential. An analyst target ($25) from Canaccord Genuity and a target ($24) from Oppenheimer hint at VERU potentially being undervalued from current chart levels. #7. Novo Nordisk Holds A Right Of First Negotiation. The Danish firm supplies Wegovy at no cost and holds first negotiation rights on combination use, so any partnering discussion involving VERU has a known starting point. In Summary What makes this name worth understanding is not one number, it is the shape of the setup. A category growing toward triple-digit scale carries a well documented side effect, and one small company has spent years building evidence and patent claims around solving it. The 16 week evidence is on the record. The 68 week test is fully enrolled with a dated readout. Protection runs deep into the 2040s. Against that sit the constraints of a pre commercial company with one lead asset. For anyone building a watchlist around the muscle preservation theme, start here. Now official: coverage is officially initiated on Veru Inc. (Nasdaq: VERU). Stay on the lookout for updates heading your way shortly. All the best, Dane James Editor Market Pulse Today (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Constant Contact Data Notice